Countries View catalog
Evidence

GHK-Cu: four decades of papers, few trials

The copper peptide is a cosmetics star and now a syringe star too. Topical trials give mixed results, the injectable route has no human trials, and about a third of the literature carries the same group's byline.

Published October 9, 2026 · 2 min read · 15 sources

From cosmetics to the syringe

GHK-Cu is a tripeptide (glycyl-histidyl-lysine) bound to copper, found in human plasma; it was first described in 1973 as a human-serum tripeptide that prolonged the survival of liver cells in culture9. It has been studied for decades for its role in wound healing and skin4. In recent years it moved from creams to injectable vials, with systemic "rejuvenation" claims.

Topical trials: mixed results

  • Diabetic ulcers (1994): a GHK-Cu gel was associated with median area closure of 98.5% vs 60.8% with vehicle1.
  • Venous ulcers (1992): 86 patients; 0.4% copper tripeptide was no better than placebo, and silver sulfadiazine was superior2.
  • Skin after CO2 laser (2006): 13 patients; no objective benefit, only higher subjective satisfaction3.

A 2026 systematic review of GHK-Cu with microneedling concluded that "clinical literature in humans remains thin and fragmented" and that no adequately powered trials exist for that route5. The preclinical base is broader: in fibroblasts it increased collagen synthesis11 and the expression of MMP-2 and its inhibitors TIMP-1 and TIMP-213; in rat wound chambers it increased collagen and glycosaminoglycans12, and in ischemic rat wounds the gel reduced wound area by 64.5% at 13 days, versus 45.6% with vehicle and 28.2% untreated14. In vitro, copper from the tripeptide penetrated isolated human skin15. But none of those models replaces a clinical trial.

86patients in the venous-ulcer trial, negative2
13patients after laser, no objective benefit3
0human trials of injectable GHK-Cu found8

Who writes the reviews?

One of the most cited GHK-Cu reviews (2018) has Loren Pickart as first author, affiliated with a cosmetics company ("R&D Skin Biology"), and declares no conflict of interest4. The 2015 review describing the age-related decline in GHK comes from the same group10. According to the 2026 systematic review, about 35% of the primary GHK-Cu literature includes Pickart or Anna Margolina (Skin Biology) as authors5. It is worth knowing when weighing that literature.

Regulatory status

In the US, the FDA split the routes: non-injectable GHK-Cu returned to Category 1 (substances under evaluation) in May 2026, and the agency announced it will consult its Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 on its potential inclusion on the 503A list6. The nomination for injectable GHK-Cu was withdrawn, and the FDA keeps it on its list of nominated-and-withdrawn substances with potential safety risks, such as immunogenicity7.

Sources

  1. Mulder GD, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. PubMed 17147644 ↗
  2. Bishop JB, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. PubMed 1495150 ↗
  3. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. PubMed 16847171 ↗
  4. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7). PubMed 29986520 ↗
  5. Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. PubMed 42787770 ↗
  6. U.S. Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A: categories (updated 14 May 2026). fda.gov ↗
  7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov ↗
  8. ClinicalTrials.gov. Búsqueda en la API v2: «GHK-Cu» y «GHK» (ningún estudio con GHK-Cu inyectable; solo estudios tópicos o transdérmicos). Búsqueda complementaria en PubMed sin ensayos clínicos de GHK-Cu inyectable. Consultado el 9 de octubre de 2026. clinicaltrials.gov ↗
  9. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-7. PubMed 4349963 ↗
  10. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PubMed 26236730 ↗
  11. Maquart FX, Pickart L, Laurent M, Gillery P, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PubMed 3169264 ↗
  12. Maquart FX, Bellon G, Chaqour B, Wegrowski J, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. PubMed 8227353 ↗
  13. Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. PubMed 11045606 ↗
  14. Canapp SO Jr, Farese JP, Schultz GS, Gowda S, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-23. PubMed 14648529 ↗
  15. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PubMed 20721598 ↗

Informational article. It summarizes news, official statements and published studies; it is not medical or legal advice. Sources were checked on the publication date.

Keep reading

Evidence

GHK-Cu (copper peptide): the mechanism of action, step by step

From copper to matrix, from matrix to cell and from cell to gene: what has actually been measured about how GHK-Cu works in skin, with every human study we could verify.

October 9, 2026 · 7 min read · 37 sources Read article → Regulation

Counterfeit Ozempic, compounded tirzepatide: indictment and recall

In September 2026 the U.S. Department of Justice charged two Indian nationals with smuggling counterfeit Ozempic from China, and FDA classified a North Carolina pharmacy's recall of compounded tirzepatide vials for lack of sterility assurance. Two fronts in the same GLP-1 supply chain.

October 27, 2026 · 6 min read · 15 sources Read article →

← All articles